Federal rescheduling of psilocybin — what's the realistic timeline for 2026?

Realistic framing: the MDMA rejection was specifically about the clinical trial data package (concerns about functional unblinding, trial design, and a single Phase 3 sponsor). Psilocybin's data package is coming from multiple independent academic groups and is generally considered stronger. The DEA formal scheduling review is ongoing. A realistically optimistic timeline: FDA could accept a New Drug Application for psilocybin-assisted therapy by 2027, with DEA rescheduling following FDA approval. 2026 federal rescheduling is unlikely but not impossible if a sponsor submits an NDA in early 2025.

The political environment matters: bipartisan support for veteran access creates a path that depression research alone might not. The VA research authorization and the executive order both signal political palatability in a way that didn't exist before. This makes a 2027–2028 federal approval timeline more plausible than it was two years ago.

Even with federal approval, don't conflate 'approved as a drug' with 'accessible.' MDMA approval, if it had happened, would have meant psilocybin available at certified treatment centers for specific diagnoses — not recreational legalization, not broad access. The Oregon/Colorado model (legal services regardless of diagnosis) is more permissive than what federal drug approval would look like.